{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T06:43:02Z","timestamp":1771051382575,"version":"3.50.1"},"reference-count":42,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["NeuroSci"],"abstract":"<jats:p>Alzheimer\u2019s disease is the most common form of dementia. Benzodiazepines are the most widely used pharmacological class in the treatment of insomnia and other sleep disorders. Some literature suggests that the chronic use of benzodiazepines is associated with the development of cognitive decline. This review aims to evaluate the use of benzodiazepines and its association with the development of Alzheimer\u2019s disease. A systematic review of the literature was carried out using the MEDLINE and Embase databases. Protocols followed the PRISMA-P 2020 methodology, and, after the analysis of the included studies, a narrative synthesis of the results was carried out. Only two cohort studies were identified that met defined eligibility criteria. In the retrospective study, a significant risk of developing Alzheimer\u2019s disease after treatment with benzodiazepines was found. In the prospective study, the prevalence of Alzheimer\u2019s disease was not associated with treatment with benzodiazepines. Results suggest that only the largest study presented a significant risk of developing Alzheimer\u2019s disease. Given the scarce scientific evidence found, it is concluded that further research on this topic is necessary.<\/jats:p>","DOI":"10.3390\/neurosci6010011","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T04:36:51Z","timestamp":1738557411000},"page":"11","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-Term Insomnia Treatment with Benzodiazepines and Alzheimer\u2019s Disease: A Systematic Review"],"prefix":"10.3390","volume":"6","author":[{"given":"Filipa Sofia","family":"Trigo","sequence":"first","affiliation":[{"name":"Faculty of Health Sciences, University of Beira Interior, 6200-506 Covilh\u00e3, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuno Cardoso","family":"Pinto","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, University of Beira Interior, 6200-506 Covilh\u00e3, Portugal"},{"name":"CICS-UBI\u2014Health Sciences Research Centre, University of Beira Interior, 6200-506 Covilh\u00e3, Portugal"},{"name":"Rise-Health, University of Beira Interior, 6200-506 Covilh\u00e3, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0653-3428","authenticated-orcid":false,"given":"Maria Vaz","family":"Pato","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, University of Beira Interior, 6200-506 Covilh\u00e3, Portugal"},{"name":"CICS-UBI\u2014Health Sciences Research Centre, University of Beira Interior, 6200-506 Covilh\u00e3, Portugal"},{"name":"Rise-Health, University of Beira Interior, 6200-506 Covilh\u00e3, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Vroom, M.M., and Dodart, J.-C. (2024). Active Immunotherapy for the Prevention of Alzheimer\u2019s and Parkinson\u2019s Disease. Vaccines, 12.","DOI":"10.3390\/vaccines12090973"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"101580","DOI":"10.1016\/j.eclinm.2022.101580","article-title":"Global and regional projections of the economic burden of Alzheimer\u2019s disease and related dementias from 2019 to 2050: A value of statistical life approach","volume":"51","author":"Nandi","year":"2022","journal-title":"EClinicalMedicine"},{"key":"ref_3","unstructured":"Loscalzo, J., Fauci, A.S., Kasper, D.L., Hauser, S.L., and Longo, D.L. (2018). Harrison\u2019s Principles of Internal Medicine, McGraw-Hill Education. [20th ed.]."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"a006239","DOI":"10.1101\/cshperspect.a006239","article-title":"Epidemiology of Alzheimer Disease","volume":"2","author":"Mayeux","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ene.13439","article-title":"Alzheimer\u2019s disease","volume":"25","author":"Lane","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Breijyeh, Z., and Karaman, R. (2020). Comprehensive Review on Alzheimer\u2019s Disease: Causes and Treatment. Molecules, 25.","DOI":"10.3390\/molecules25245789"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Silva, M.V.F., Loures, C.d.M.G., Alves, L.C.V., de Souza, L.C., Borges, K.B.G., and Carvalho, M.d.G. (2019). Alzheimer\u2019s disease: Risk factors and potentially protective measures. J. Biomed. Sci., 26.","DOI":"10.1186\/s12929-019-0524-y"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.37765\/ajmc.2020.42769","article-title":"Insomnia overview: Epidemiology, pathophysiology, diagnosis and monitoring, and nonpharmacologic therapy","volume":"26","author":"Dopheide","year":"2020","journal-title":"Am. J. Manag. Care"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"780","DOI":"10.4103\/2249-4863.201153","article-title":"Prevalence of chronic insomnia in adult patients and its correlation with medical comorbidities","volume":"5","author":"Bhaskar","year":"2016","journal-title":"J. Family Med. Prim. Care"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Bjor\u00f8y, I., J\u00f8rgensen, V.A., Pallesen, S., and Bjorvatn, B. (2020). The Prevalence of Insomnia Subtypes in Relation to Demographic Characteristics, Anxiety, Depression, Alcohol Consumption and Use of Hypnotics. Front. Psychol., 11.","DOI":"10.3389\/fpsyg.2020.00527"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/jsr.12594","article-title":"European guideline for the diagnosis and treatment of insomnia","volume":"26","author":"Riemann","year":"2017","journal-title":"J. Sleep Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1124\/pr.117.014381","article-title":"Drugs for Insomnia beyond Benzodiazepines: Pharmacology. Clinical Applications, and Discovery","volume":"70","author":"Atkin","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.2146\/ajhp160381","article-title":"Benzodiazepine use and cognitive decline in the elderly","volume":"75","author":"Picton","year":"2018","journal-title":"Am. J. Health-Syst. Pharm."},{"key":"ref_14","unstructured":"Ritter, J.M., Flower, R.J., Henderson, G., Loke, Y.K., MacEwan, D., and Rang, H.P. (2018). Rang and Dale\u2019s Pharmacology, Elsevier. [9th ed.]."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11920-016-0727-9","article-title":"Benzodiazepine Misuse in the Elderly: Risk Factors, Consequences, and Management","volume":"18","author":"Airagnes","year":"2016","journal-title":"Curr. Psychiatry Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/arclin\/acx120","article-title":"The Residual Medium and Long-term Cognitive Effects of Benzodiazepine Use: An Updated Meta-analysis","volume":"33","author":"Crowe","year":"2018","journal-title":"Arch. Clin. Neuropsychol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00004714-200206000-00009","article-title":"Long-Term Benzodiazepine Use and Cognitive Decline in the Elderly: The Epidemiology of Vascular Aging Study","volume":"22","author":"Paterniti","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e6231","DOI":"10.1136\/bmj.e6231","article-title":"Benzodiazepine use and risk of dementia: Prospective population based study","volume":"345","author":"Begaud","year":"2012","journal-title":"BMJ"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41593-022-01013-9","article-title":"Long-term diazepam treatment enhances microglial spine engulfment and impairs cognitive performance via the mitochondrial 18\u2009kDa translocator protein (TSPO)","volume":"25","author":"Shi","year":"2022","journal-title":"Nat. Neurosci."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"vom Hofe, I., Stricker, B.H., Vernooij, M.W., Ikram, M.K., Ikram, M.A., and Wolters, F.J. (2024). Benzodiazepine use in relation to long-term dementia risk and imaging markers of neurodegeneration: A population-based study. BMC Med., 22.","DOI":"10.1186\/s12916-024-03437-5"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"g5205","DOI":"10.1136\/bmj.g5205","article-title":"Benzodiazepine use and risk of Alzheimer\u2019s disease: Case-control study","volume":"349","author":"Moride","year":"2014","journal-title":"BMJ"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40263-016-0404-x","article-title":"Benzodiazepine Use and Risk of Developing Alzheimer\u2019s Disease: A Case-Control Study Based on Swiss Claims Data","volume":"31","author":"Pfeil","year":"2017","journal-title":"CNS Drugs"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Munn, Z., and Aromataris, E. (2020). Chapter 7: Systematic reviews of etiology and risk. JBI Manual for Evidence Synthesis, JBI.","DOI":"10.46658\/JBIRM-17-01"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"JROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res. Synth. Methods"},{"key":"ref_27","first-page":"e10047","article-title":"What\u2019s the Risk: Differentiating Risk Ratios, Odds Ratios, and Hazard Ratios?","volume":"12","author":"George","year":"2020","journal-title":"Cureus"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Lee, J., Jung, S.J., Choi, J., Shin, A., and Lee, Y.J. (2018). Use of sedative-hypnotics and the risk of Alzheimer\u2019s dementia: A retrospective cohort study. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0204413"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/1060028019882037","article-title":"Is Benzodiazepine Use Associated With the Risk of Dementia and Cognitive Impairment\u2013Not Dementia in Older Persons? The Canadian Study of Health and Aging","volume":"54","author":"Nafti","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"437","DOI":"10.31887\/DCNS.2016.18.4\/cepperson","article-title":"Considering sex and gender in Alzheimer disease and other dementias","volume":"18","author":"Podcasy","year":"2016","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_31","unstructured":"Gauthier, S., Rosa-Neto, P., and Morais, J.A. (2021). World Alzheimer Report 2021: Journey Through the Diagnosis Of Dementia, Alzheimer\u2019s Disease International."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(02)07451-2","article-title":"Bias and causal associations in observational research","volume":"359","author":"Grimes","year":"2002","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/00461520.2016.1207177","article-title":"Quasi-Experimental Designs for Causal Inference","volume":"51","author":"Kim","year":"2016","journal-title":"Educ. Psychol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1177\/00220345221084283","article-title":"Causal Inference: Onward and Upward!","volume":"101","author":"Listl","year":"2022","journal-title":"J. Dent. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s40264-015-0319-3","article-title":"Benzodiazepine Use and Risk of Developing Alzheimer\u2019s Disease or Vascular Dementia: A Case\u2013Control Analysis","volume":"38","author":"Imfeld","year":"2015","journal-title":"Drug Saf."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"i90","DOI":"10.1136\/bmj.i90","article-title":"Benzodiazepine use and risk of incident dementia or cognitive decline: Prospective population based study","volume":"352","author":"Gray","year":"2016","journal-title":"BMJ"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3233\/JAD-201319","article-title":"Association between the Use of Hypnotics and the Risk of Alzheimer\u2019s Disease","volume":"81","author":"Jeong","year":"2021","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/B978-0-444-53817-8.00002-5","article-title":"Sleep-wake changes and cognition in neurodegenerative disease","volume":"190","author":"Naismith","year":"2011","journal-title":"Prog. Brain Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11940-020-0612-z","article-title":"Therapy for Insomnia and Circadian Rhythm Disorder in Alzheimer Disease","volume":"22","author":"Galbiati","year":"2020","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.3233\/JAD-201582","article-title":"Insomnia Moderates the Relationship between Amyloid-\u03b2 and Cognitive Decline in Late-Life Adults without Dementia","volume":"81","author":"Xu","year":"2021","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1212\/WNL.0000000000005047","article-title":"Author response: Sleep architecture and the risk of incident dementia in the community","volume":"90","author":"Pase","year":"2018","journal-title":"Neurology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"89","DOI":"10.9758\/cpn.2017.15.2.89","article-title":"Role of Sleep Disturbance in the Trajectory of Alzheimer\u2019s Disease","volume":"15","author":"Kang","year":"2017","journal-title":"Clin. Psychopharmacol. Neurosci."}],"container-title":["NeuroSci"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2673-4087\/6\/1\/11\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:25:41Z","timestamp":1760027141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2673-4087\/6\/1\/11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["neurosci6010011"],"URL":"https:\/\/doi.org\/10.3390\/neurosci6010011","relation":{},"ISSN":["2673-4087"],"issn-type":[{"value":"2673-4087","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,1]]}}}